SI3402801T1 - Ciklični dinukleotidi za zdravljenje stanj, povezanih z aktivnostjo sting, kot je rak - Google Patents
Ciklični dinukleotidi za zdravljenje stanj, povezanih z aktivnostjo sting, kot je rakInfo
- Publication number
- SI3402801T1 SI3402801T1 SI201731621T SI201731621T SI3402801T1 SI 3402801 T1 SI3402801 T1 SI 3402801T1 SI 201731621 T SI201731621 T SI 201731621T SI 201731621 T SI201731621 T SI 201731621T SI 3402801 T1 SI3402801 T1 SI 3402801T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cancer
- conditions associated
- treating conditions
- cyclic dinucleotides
- sting activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277273P | 2016-01-11 | 2016-01-11 | |
| US201662436759P | 2016-12-20 | 2016-12-20 | |
| EP17704338.7A EP3402801B1 (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| PCT/US2017/013066 WO2017123669A1 (en) | 2016-01-11 | 2017-01-11 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3402801T1 true SI3402801T1 (sl) | 2025-10-30 |
Family
ID=58010371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201731621T SI3402801T1 (sl) | 2016-01-11 | 2017-01-11 | Ciklični dinukleotidi za zdravljenje stanj, povezanih z aktivnostjo sting, kot je rak |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10604542B2 (enExample) |
| EP (1) | EP3402801B1 (enExample) |
| JP (1) | JP6867395B2 (enExample) |
| KR (2) | KR102789862B1 (enExample) |
| CN (1) | CN109451740B (enExample) |
| AU (1) | AU2017207757B2 (enExample) |
| BR (1) | BR112018013808A2 (enExample) |
| CA (1) | CA3011528A1 (enExample) |
| CL (1) | CL2018001870A1 (enExample) |
| CO (1) | CO2018008196A2 (enExample) |
| DK (1) | DK3402801T3 (enExample) |
| EA (1) | EA036421B1 (enExample) |
| ES (1) | ES3046957T3 (enExample) |
| FI (1) | FI3402801T3 (enExample) |
| HR (1) | HRP20251050T1 (enExample) |
| HU (1) | HUE073018T2 (enExample) |
| IL (1) | IL260427B (enExample) |
| LT (1) | LT3402801T (enExample) |
| MX (1) | MX2018008266A (enExample) |
| MY (1) | MY194058A (enExample) |
| PE (1) | PE20181330A1 (enExample) |
| PL (1) | PL3402801T3 (enExample) |
| PT (1) | PT3402801T (enExample) |
| RS (1) | RS67188B1 (enExample) |
| SG (1) | SG11201805888SA (enExample) |
| SI (1) | SI3402801T1 (enExample) |
| SM (1) | SMT202500412T1 (enExample) |
| WO (1) | WO2017123669A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| MX2018001814A (es) | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
| HUE073018T2 (hu) * | 2016-01-11 | 2026-01-28 | Innate Tumor Immunity Inc | Ciklikus dinukleotidok állapotok kezelésére, amelyek STING-aktivitással kapcsolatosak, mint például rák |
| CN114751950B (zh) | 2016-03-18 | 2025-04-18 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| KR102569881B1 (ko) | 2016-07-06 | 2023-08-22 | 에프-스타 테라퓨틱스 인코포레이티드 | 질병 치료용 화합물, 조성물 및 방법 |
| DK3922279T3 (da) | 2016-08-30 | 2025-02-03 | Dana Farber Cancer Inst Inc | Præparater til lægemiddelafgivelse og anvendelse heraf |
| US10414747B2 (en) | 2016-10-04 | 2019-09-17 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene compounds as sting agonists |
| PT3512861T (pt) | 2016-12-01 | 2021-04-29 | Takeda Pharmaceuticals Co | Dinucleotídeos cíclicos |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| WO2018190719A2 (en) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| US11259980B2 (en) | 2017-07-31 | 2022-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Soft inflatable exosuit for knee rehabilitation |
| JP2020530838A (ja) | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
| KR102782200B1 (ko) | 2017-08-30 | 2025-03-17 | 에이제이 사이언시즈 (이씽) 코., 엘티디 | 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드 |
| EP3676277A1 (en) * | 2017-08-31 | 2020-07-08 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| US11638716B2 (en) | 2017-08-31 | 2023-05-02 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| WO2019051489A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| IL273274B2 (en) | 2017-09-14 | 2023-12-01 | Janssen Biopharma Llc | Modified nucleoside phosphoramidites |
| WO2019074887A1 (en) * | 2017-10-10 | 2019-04-18 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| MX2020004858A (es) | 2017-11-10 | 2020-10-01 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso. |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
| EP3727401A4 (en) | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS |
| EP3505527A1 (en) * | 2017-12-29 | 2019-07-03 | Invivogen | Cyclic dinucleotides for cytokine induction |
| US10519187B2 (en) * | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| US11945834B2 (en) * | 2018-03-08 | 2024-04-02 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| EP4242212A3 (en) | 2018-03-23 | 2023-11-15 | Takeda Pharmaceutical Company Limited | Sting modulator compounds with sulfamate linkages, and methods of making and using |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| EP3774764A1 (en) | 2018-04-03 | 2021-02-17 | Merck Sharp&Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| ES2929415T3 (es) | 2018-05-25 | 2022-11-29 | Incyte Corp | Compuestos heterocíclicos tricíclicos como activadores de STING |
| US12291548B2 (en) | 2018-07-10 | 2025-05-06 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| MX2020013322A (es) | 2018-08-16 | 2021-02-22 | Eisai R&D Man Co Ltd | Sales de compuestos y cristales de los mismos. |
| TWI905974B (zh) | 2018-09-06 | 2025-11-21 | 日商第一三共股份有限公司 | 抗體藥物結合物之用途 |
| JP2022500414A (ja) | 2018-09-12 | 2022-01-04 | シルバーバック セラピューティックス インコーポレイテッド | 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物 |
| WO2020057546A1 (zh) | 2018-09-21 | 2020-03-26 | 上海迪诺医药科技有限公司 | 环状二核苷酸类似物、其药物组合物及应用 |
| EP3873484B1 (en) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Novel sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020089815A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| BR112021010466A2 (pt) * | 2018-12-04 | 2021-08-24 | Bristol-Myers Squibb Company | Processo para a preparação de um dinucleotídeo cíclico |
| WO2020146237A1 (en) | 2019-01-07 | 2020-07-16 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| JP2022523141A (ja) * | 2019-02-05 | 2022-04-21 | ブリストル－マイヤーズ スクイブ カンパニー | ３’－アミノ－３’－デオキシアデノシンおよび３’－アミノ－３’－デオキシグアノシンならびにその保護された誘導体を製造するための中間体としての１，２，５－トリ－ｏ－ベンゾイル－３－ジベンジルアミノ－３－デオキシリボースの合成 |
| CA3139809A1 (en) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| JP7622031B2 (ja) | 2019-07-05 | 2025-01-27 | タンボ・インコーポレイテッド | トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| US12435104B2 (en) * | 2019-07-25 | 2025-10-07 | Beigene, Ltd. | Cyclic dinucleotides as sting agonists |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| CN115176000A (zh) | 2019-12-26 | 2022-10-11 | 国立大学法人东海国立大学机构 | 多核苷酸及医药组合物 |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230330248A1 (en) | 2020-03-06 | 2023-10-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| EP4138852A4 (en) * | 2020-04-21 | 2024-05-15 | Duke University | COMPOSITIONS AND METHODS FOR TREATING PAIN |
| EP4149440A1 (en) | 2020-05-11 | 2023-03-22 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
| AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
| US12589162B2 (en) | 2020-08-07 | 2026-03-31 | Tambo, Inc. | Trans-cyclooctene prodrug of monomethyl auristatin E |
| KR20230061360A (ko) | 2020-09-02 | 2023-05-08 | 다이이찌 산쿄 가부시키가이샤 | 신규 엔도-β-N-아세틸글루코사미니다아제 |
| US20240277751A1 (en) * | 2020-10-15 | 2024-08-22 | The Regents Of The University Of Michigan | Crystalline polymorphic forms of sting agonists associated with metal ions capable of modulating an immune response |
| KR102466750B1 (ko) | 2020-10-23 | 2022-11-15 | 아주대학교산학협력단 | 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| EP4237012A1 (en) | 2020-10-30 | 2023-09-06 | Avacta Life Sciences Limited | Fap-activated serum extended half-life therapeutic conjugates |
| MX2023005381A (es) | 2020-11-09 | 2023-05-23 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco. |
| WO2023277168A1 (ja) | 2021-06-30 | 2023-01-05 | 協和キリン株式会社 | ポリヌクレオチド及び医薬組成物 |
| TW202346322A (zh) | 2022-03-02 | 2023-12-01 | 日商第一三共股份有限公司 | 含Ｆｃ分子之製造方法 |
| IL319250A (en) | 2022-08-29 | 2025-04-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate including a mutant FC region |
| WO2026027944A1 (en) | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Anti-sirp alpha antibody formulations and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| CA2490626A1 (en) | 2002-06-20 | 2003-12-31 | Nippon Suisan Kaisha, Ltd. | Prodrug, medicinal utilization thereof and process for producing the same |
| JP4931798B2 (ja) * | 2004-03-15 | 2012-05-16 | ケイ．アール． カラオリス，デイヴィッド | 免疫、炎症または神経保護応答のための方法 |
| AU2013263076B2 (en) * | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| NZ702392A (en) | 2012-06-08 | 2017-03-31 | Aduro Biotech | Compositions and methods for cancer immunotherapy |
| EA201590396A1 (ru) * | 2012-12-13 | 2015-12-30 | Адуро Биотек, Инк. | Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения |
| ES2982836T3 (es) | 2013-04-29 | 2024-10-17 | Memorial Sloan Kettering Cancer Center | Composiciones y métodos para alterar la señalización de segundos mensajeros |
| ME03586B (me) | 2013-05-18 | 2020-07-20 | Univ California | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon" |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| EP3060056A4 (en) | 2013-10-21 | 2017-10-18 | Drexel University | Use of sting agonists to treat chronic hepatitis b virus infection |
| EP3071209A4 (en) | 2013-11-19 | 2017-08-16 | The University of Chicago | Use of sting agonist as cancer treatment |
| WO2015077534A1 (en) | 2013-11-22 | 2015-05-28 | Massachusetts Institute Of Technology | Photovoltaic power balancing and differential power processing |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| WO2015185565A1 (en) | 2014-06-04 | 2015-12-10 | Glaxosmithkline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| US20170340658A1 (en) | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| ES2764178T3 (es) | 2014-12-16 | 2020-06-02 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para inducción de citocinas |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| MX2018001814A (es) | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド |
| HUE073018T2 (hu) * | 2016-01-11 | 2026-01-28 | Innate Tumor Immunity Inc | Ciklikus dinukleotidok állapotok kezelésére, amelyek STING-aktivitással kapcsolatosak, mint például rák |
| CN114751950B (zh) | 2016-03-18 | 2025-04-18 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
-
2017
- 2017-01-11 HU HUE17704338A patent/HUE073018T2/hu unknown
- 2017-01-11 KR KR1020187022863A patent/KR102789862B1/ko active Active
- 2017-01-11 KR KR1020257010190A patent/KR20250049441A/ko active Pending
- 2017-01-11 SM SM20250412T patent/SMT202500412T1/it unknown
- 2017-01-11 LT LTEPPCT/US2017/013066T patent/LT3402801T/lt unknown
- 2017-01-11 ES ES17704338T patent/ES3046957T3/es active Active
- 2017-01-11 SI SI201731621T patent/SI3402801T1/sl unknown
- 2017-01-11 PT PT177043387T patent/PT3402801T/pt unknown
- 2017-01-11 CA CA3011528A patent/CA3011528A1/en active Pending
- 2017-01-11 WO PCT/US2017/013066 patent/WO2017123669A1/en not_active Ceased
- 2017-01-11 PE PE2018001267A patent/PE20181330A1/es unknown
- 2017-01-11 AU AU2017207757A patent/AU2017207757B2/en active Active
- 2017-01-11 DK DK17704338.7T patent/DK3402801T3/da active
- 2017-01-11 SG SG11201805888SA patent/SG11201805888SA/en unknown
- 2017-01-11 EP EP17704338.7A patent/EP3402801B1/en active Active
- 2017-01-11 US US15/748,685 patent/US10604542B2/en active Active
- 2017-01-11 JP JP2018536116A patent/JP6867395B2/ja active Active
- 2017-01-11 CN CN201780015198.2A patent/CN109451740B/zh active Active
- 2017-01-11 RS RS20250892A patent/RS67188B1/sr unknown
- 2017-01-11 BR BR112018013808-8A patent/BR112018013808A2/pt active Search and Examination
- 2017-01-11 PL PL17704338.7T patent/PL3402801T3/pl unknown
- 2017-01-11 EA EA201891565A patent/EA036421B1/ru not_active IP Right Cessation
- 2017-01-11 HR HRP20251050TT patent/HRP20251050T1/hr unknown
- 2017-01-11 MX MX2018008266A patent/MX2018008266A/es unknown
- 2017-01-11 MY MYPI2018702369A patent/MY194058A/en unknown
- 2017-01-11 FI FIEP17704338.7T patent/FI3402801T3/fi active
-
2018
- 2018-07-04 IL IL260427A patent/IL260427B/en active IP Right Grant
- 2018-07-10 CL CL2018001870A patent/CL2018001870A1/es unknown
- 2018-08-02 CO CONC2018/0008196A patent/CO2018008196A2/es unknown
-
2020
- 2020-01-31 US US16/778,281 patent/US10961270B2/en active Active
-
2021
- 2021-01-28 US US17/160,578 patent/US11505571B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260427B (en) | Circular dinucleotides for the treatment of conditions related to sting activity such as cancer | |
| ZA201704732B (en) | Cyclic dinucleotides useful for the treatment of inter alia cancer | |
| ZA201705673B (en) | Methods for treating skin | |
| ZA201804227B (en) | Methods of treating cancer | |
| ZA201706616B (en) | Method for treating cancer | |
| IL265335A (en) | Treating cluster headache | |
| IL255189A0 (en) | Cancer treatment methods | |
| IL266766B (en) | Dioxolane analog of uridine for cancer treatment | |
| IL252610A0 (en) | Methods and preparations for the treatment of cancer | |
| IL255060A0 (en) | Combined treatment for cancer | |
| IL256836B (en) | Methods for treating cancer using apilimod | |
| IL257691A (en) | A method for treating cancer | |
| IL254393A0 (en) | Methods for treating diseases associated with pathological changes in protein | |
| IL255022A0 (en) | Cancer treatment methods | |
| IL268463A (en) | Cancer treatment | |
| SG11201605070UA (en) | Novel methods for treating cancer | |
| IL255018A0 (en) | Cancer treatment methods | |
| SG10201508795XA (en) | Method for treating cancer | |
| IL255016A0 (en) | Cancer treatment methods | |
| IL255012A0 (en) | Preparations and methods for treating skin conditions | |
| GB201516482D0 (en) | Gas treatment assembly | |
| HK1240933A1 (en) | Cyclic dinucleotides useful for the treatment of inter alia cancer | |
| AU2015903130A0 (en) | Methods for treating tumours |